Postgrad LIVE! Study Fairs

Birmingham | Edinburgh | Liverpool | Sheffield | Southampton | Bristol

London School of Hygiene & Tropical Medicine Featured PhD Programmes
Swansea University Featured PhD Programmes
University of Oxford Featured PhD Programmes
University College London Featured PhD Programmes
University College London Featured PhD Programmes
10 miles

University of Oxford Medical / Clinical Science PhD Projects, Programs & Scholarships

We have 82 University of Oxford Medical / Clinical Science PhD Projects, Programs & Scholarships

  • Medical / Clinical Science×
  • University of Oxford×
  • clear all
Order by 
Showing 1 to 10 of 82
  Using AI to Drive Drug Discovery for Membrane Protein Targets
  Dr PC Biggin
Application Deadline: 11 January 2019
Lead supervisor. Prof Phil Biggin, Department of Biochemistry, Oxford. Commercial partner. Vertex Pharmaceuticals, Milton site, Oxfordshire.
  An Enhanced Transcranial Magnetic Stimulator for Advancing Clinical Neuroscience and Minimally-Invasive Brain Therapies
  Prof T Denison
Application Deadline: 11 January 2019
Commercial partner. Magstim, Whitland, Wales. Transcranial Magnetic Stimulation (TMS) is a non-invasive technology to stimulate brain circuits.
  Optimisation of co-registered functional near-infrared spectroscopy and electroencephalogram measurement of early childhood neurocognitive development
  Dr G Scerif, Dr K Holmboe
Application Deadline: 11 January 2019
Gowerlabs Ltd, London. Functional Near-Infrared Spectroscopy (fNIRS) is a relatively new optical imaging technique that enables non-invasive assessment of functional brain activation outside a scanner environment.
  Deciphering the regulation of non-coding RNAs in a hypoxic tumour microenvironment
  Prof F Buffa, Prof A Harris
Application Deadline: 11 January 2019
The role of the microenvironment in driving tumour progression is increasingly recognized. Hypoxia is one of the key microenvironmental changes between tumour and normal tissue, and adaptation of cancer cells to this hostile environment contributes to their malignancy and aggressive phenotype (1).
  Dissecting the Determinants of Response to Checkpoint Inhibitors
  Dr B Fairfax, Prof M Middleton
Application Deadline: 11 January 2019
Cancer treatment is being revolutionised by checkpoint inhibitor immunotherapy (CKI). In melanoma, where there is limited role for radiotherapy or chemotherapy, CKI forms the frontline treatment.
  Hypoxia-Targeted Protein-Targeting Chimeras (htPROTACS)
  Prof E Hammond, Dr S Conway
Application Deadline: 11 January 2019
Protein-targeting chimeras (PROTACS) are bifunctional molecules that hijack the cellular machinery for protein degradation, via the ubiquitination pathway, to target the degradation of a defined target protein.
  Investigating the Contribution of IGF-1 to Risk of Developing Prostate Cancer
  Prof V Macaulay, Prof I Mills
Application Deadline: 11 September 2019
Subjects with low circulating insulin-like growth factor-1 (IGF-1) are strongly protected from cancer, while men with high IGF-1 are at increased risk of prostate cancer.
  Investigating the Potential Benefits of MRI-LINAC for Delivery of Stereotactic Ablative Radiotherapy (SBRT) in Hepatobiliary Malignancies
  Dr M Hawkins, Prof F Van den Heuvel
Application Deadline: 11 January 2019
SBRT has been investigated as an alternative to conventionally fractionated radiotherapy for the local treatment of pancreatic cancer and liver malignancies.
  Investigating the role of Ribonucleotide Reductase (RNR) in cell physiology and cancer
  Dr V D'Angiolella, Dr R Chapman
Application Deadline: 11 January 2019
Normal cells coordinate the production of deoxyribonucleotides (dNTPs) with DNA replication. On the contrary, cancer cells proliferate uncontrollably and need to balance faster DNA replication with a high demand for dNTPs.
  The IGF axis as a mediator of treatment resistance in glioblastoma multiforme
  Prof V Macaulay, Prof N Sibson
Application Deadline: 11 January 2019
Despite multimodality treatment with surgery, ionising radiation (IR) and chemotherapy, the outlook for patients with glioblastoma multiforme (GBM) is extremely poor.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2018
All rights reserved.